Dengue Fever

Detailed Overview

Dengue is transmitted primarily by Aedes aegypti mosquitoes. Infection with one serotype provides lifelong immunity to that specific serotype, but only temporary cross-immunity to the others. Paradoxically, secondary infection with a different serotype drastically increases the risk of severe dengue through a mechanism known as antibody-dependent enhancement (ADE). The critical phase of the illness occurs around the time the fever drops, where profound vascular permeability can lead to hypovolemic shock (Dengue Shock Syndrome) and multiorgan failure.

Epidemiology & Demographics

Endemic in >100 countries in tropical and subtropical regions (Southeast Asia, Americas, Western Pacific). Affects an estimated 390 million people annually, causing 500,000 hospitalizations for severe dengue and 25,000 deaths.

Etiological Mechanism

Infection by Dengue virus (DENV 1, 2, 3, or 4), an RNA virus of the Flaviviridae family. Transmitted primarily by the daytime-biting female Aedes aegypti and Aedes albopictus mosquitoes.

Primary Causes

Bite from an infected Aedes mosquito.

• Travel to Endemic Areas: Recent travel to Southeast Asia, Caribbean, Latin America, or the Pacific Islands.
• Secondary Infection: Prior infection with a different Dengue serotype is the strongest risk factor for Severe Dengue (Dengue Hemorrhagic Fever) due to ADE.
• Age: Children < 15 years are at a significantly higher risk for severe dengue.

Following a mosquito bite, the virus replicates in local dendritic cells and regional lymph nodes, resulting in viremia. Symptoms arise from the robust immune response, particularly the release of cytokines. In primary infection, memory T and B cells are formed. If a secondary infection with a different serotype occurs, pre-existing, non-neutralizing antibodies from the first infection bind to the new virus. Instead of neutralizing it, they facilitate entry into macrophages via Fc-receptors (Antibody-Dependent Enhancement). This causes massive viral replication and a devastating 'cytokine storm' (TNF-alpha, IL-6). The cytokines severely disrupt endothelial cell tight junctions, causing profound plasma leakage into the pleural and peritoneal cavities. Simultaneously, bone marrow suppression and immune destruction cause severe thrombocytopenia, while coagulopathy leads to hemorrhagic manifestations.

Characteristic Clinical Presentation

• Sudden High Fever: Biphasic (saddleback) fever often reaching 40°C (104°F).
• Severe Myalgias and Arthralgias: Excruciating deep bone and muscle pain, giving the namesake 'Breakbone Fever'.
• Retro-orbital Pain: Severe pain behind the eyes, worsened by eye movement.
• Maculopapular Rash: Appears 3-4 days after fever onset, often described as 'islands of white in a sea of red'.

Physical Examination Signs

• Positive Tourniquet Test (appearance of >10 petechiae per square inch after inflating a BP cuff midway between systolic and diastolic for 5 minutes).
• Hepatomegaly (often tender).
• Signs of plasma leakage (pleural effusion, ascites).
• Bleeding manifestations (epistaxis, gingival bleeding, purpura, melena).

• Dengue Shock Syndrome (DSS): Profound hypovolemic shock due to massive plasma leakage out of the vascular space.
• Severe Hemorrhage: Gastrointestinal bleeding or intracranial hemorrhage due to severe thrombocytopenia and coagulopathy.
• Organ Impairment: Severe hepatitis (AST/ALT > 1000), myocarditis, or dengue encephalitis.

Diagnostic Criteria & Guidelines

Diagnosis is suspected in patients with acute febrile illness and relevant travel history, plus two clinical signs (nausea, rash, aches, tourniquet test, leukopenia). Confirmed via viral isolation, PCR, or NS1 antigen detection in early illness, or IgM/IgG serology later.

Differential Diagnosis

• Malaria (requires thick/thin blood smear)
• Chikungunya (causes more severe, chronic joint pain but no plasma leak)
• Zika Virus (prominent conjunctivitis, milder fever)
• Typhoid Fever
• Leptospirosis

Laboratory Tests & Biomarkers

• NS1 Antigen Test: Highly specific. Positive during the first 1-5 days (febrile phase).
• Complete Blood Count: Progressive leukopenia followed by a rapid, severe thrombocytopenia (platelets often < 50,000/mcL).
• Hematocrit: A rising hematocrit (>20% increase from baseline) is the hallmark sign of hemoconcentration due to plasma leakage, heralding the critical phase.
• Dengue IgM/IgG ELISA: IgM becomes positive after day 5. IgG presence indicates secondary infection.

Imaging Modalities & Findings

• Chest X-Ray / Bedside Ultrasound:

• Febrile Phase
  Days 1-3. High fever, severe pain, headache, positive tourniquet test.
• Critical Phase
  Days 4-6. Occurs precisely when the fever drops (defervescence). Characterized by systemic vascular leak, rapid drop in platelets, and risk of shock/hemorrhage.
• Recovery Phase
  Days 7-10. Resorption of leaked fluids, rising platelets, resolution of symptoms, and intense pruritus.

Second-Line & Adjunctive Therapy

For Warning Signs or Severe Dengue (Critical Phase): Hospital admission and meticulous, protocol-driven IV fluid resuscitation using isotonic crystalloids (e.g., Ringer's Lactate or Normal Saline). The fluid rate must be titrated closely based on hourly urine output and hematocrit levels. Transfusion of packed RBCs if severe overt bleeding occurs. Platelet transfusions are generally NOT recommended for thrombocytopenia alone unless there is massive bleeding.

Surgical & Procedural Management

Not indicated.

Recommended Lifestyle Changes

• Rigorous mosquito bite prevention: use of DEET-containing repellents, wearing long sleeves, and staying in air-conditioned or screened-in environments.
• Eliminate standing water around the home (flower pots, tires) where Aedes mosquitoes breed.

Patient Counseling & Advice

Instruct the patient that the most dangerous time in Dengue is paradoxically when the fever breaks (usually around day 4-5). They must seek immediate emergency care if they develop severe abdominal pain, persistent vomiting, mucosal bleeding, or lethargy at this time. Warn explicitly against using ibuprofen or aspirin.

Follow-Up & Monitoring Schedule

Outpatient management requires daily CBC checks specifically to monitor the trend of platelets and hematocrit until the patient successfully passes the critical phase.

Preventive Strategies

Vector control is paramount. The CYD-TDV (Dengvaxia) vaccine is available, but ONLY for individuals aged 9-45 who have had a laboratory-confirmed PREVIOUS dengue infection. Giving the vaccine to seronegative individuals paradoxically increases their risk of severe dengue upon future natural infection.

For uncomplicated dengue, the prognosis is excellent with a 1-2 week recovery. However, mortality in severe dengue can approach 20% if left untreated, but drops to <1% with meticulous fluid management in a hospital setting.